Spero Therapeutics (SPRO) Non Operating Income (2017 - 2026)
Spero Therapeutics' (SPRO) quarterly Non Operating Income came in at $335000.0 in Q1 2026, down 61.27% YoY from $865000.0 in Q1 2025, and down 10.9% on a QoQ basis from $376000.0 in Q4 2025.
Spero Therapeutics (SPRO) Non Operating Income (2017 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of Non Operating Income data on file, last reported at $335000.0 in Q1 2026.
- Quarterly Non Operating Income fell 61.27% year-over-year to $335000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 54.24% YoY) and the FY2025 annual result came in at $2.5 million, down 47.47% from the prior year.
- Non Operating Income retreated to $335000.0 in Q1 2026, from $376000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.3 million in Q1 2024 to a low of -$2.6 million in Q1 2022.
- A 5-year average of $432588.2 and a median of $865000.0 in 2025 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 5200.0% in 2022, down 13010.0% in 2022.
- Tracing SPRO's Non Operating Income over 5 years: stood at $847000.0 in 2022, then grew by 23.49% to $1.0 million in 2023, then gained by 7.74% to $1.1 million in 2024, then tumbled by 66.64% to $376000.0 in 2025, then slipped by 10.9% to $335000.0 in 2026.
- The last three Non Operating Income figures came in at $335000.0 (Q1 2026), $376000.0 (Q4 2025), and $534000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 374,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 374,000.00 |
| Mar 31, 2026 | 335,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 534,000.00 |
| Jun 30, 2025 | 744,000.00 |
| Mar 31, 2025 | 865,000.00 |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 1.16 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 940,000.00 |
| Jun 30, 2023 | 976,000.00 |
| Mar 31, 2023 | 961,000.00 |
| Dec 31, 2022 | 847,000.00 |
| Sep 30, 2022 | 159,000.00 |
| Jun 30, 2022 | -2.60 Mn |
| Mar 31, 2022 | -2.62 Mn |
| Dec 31, 2021 | -1.74 Mn |
| Sep 30, 2021 | 3,000.00 |